^
    Back
    Association details:
    Biomarker:IDH1 mutation + MGMT promoter methylation
    Cancer:Glioblastoma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Biol Med
    Title:

    Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma

    Published date:
    02/15/2021
    Excerpt:
    ...50 IDH-mutant glioblastomas receiving temozolomide therapy (cohort A). The median progression-free survival and median overall survival in cohort A were 9.33…confirmed that the MGMT promoter methylation was significantly (P = 0.0001) correlated with longer OS in IDH-mutant patients with GBM...
    DOI:
    10.20892/j.issn.2095-3941.2020.0179
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer Sci
    Title:

    IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

    Excerpt:
    Further analysis of response to temozolomide showed that patients with both IDH mutation and MGMT promoter methylation had the best response rate to temozolomide.
    DOI:
    10.1111/j.1349-7006.2011.02134.x